NCT04654416 is a clinical trial of Corticosteroid with or without colchicine in Covid-19, sponsored by Clínica Medellín - Grupo Quirónsalud.

Who is sponsoring NCT04654416?

NCT04654416 is sponsored by Clínica Medellín - Grupo Quirónsalud.

What drugs are being tested in NCT04654416?

Interventions in NCT04654416: Corticosteroid with or without colchicine.

Is NCT04654416 still recruiting?

NCT04654416 is currently completed. Last updated 4 December 2020.

Last reviewed 2020-12-04 · How we verify

NCT04654416

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine

Completed Last updated 4 December 2020

What this trial tests

trial testing Corticosteroid with or without colchicine in Covid-19 in 301 participants. Completed in 20 August 2020.

Timeline

20 March 2020

Primary endpoint
7 August 2020

20 August 2020

Quick facts

Lead sponsor	Clínica Medellín - Grupo Quirónsalud
Status	Completed
Study type	OBSERVATIONAL
Enrollment	301
Start date	20 March 2020
Primary completion	7 August 2020
Estimated completion	20 August 2020
Sites	1 location across Colombia

Drugs / interventions tested

Corticosteroid with or without colchicine — full drug profile →

Conditions studied

Covid-19 — all drugs for Covid-19 →

Sponsor

Clínica Medellín - Grupo Quirónsalud — full company profile →

Who can join

18 and older, any sex, with Covid-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cross sectional study of 301 adult patients with Covid-19 Pneumonia treated with corticosteroid and/or colchicine

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The intersection of COVID-19 and cancer: signaling pathways and treatment implications.
Zong Z, Wei Y, Ren J, Zhang L, et al · · 2021 · cited 54× · PMID 34001144 · DOI 10.1186/s12943-021-01363-1
Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis.
Gopalaswamy R, Subbian S. · · 2021 · cited 52× · PMID 33917321 · DOI 10.3390/ijms22073773
Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection.
Marmitt DJ. · · 2022 · cited 1× · PMID 35389124 · DOI 10.1007/s10787-022-00981-5

Verify or expand the search:

Other recruiting trials for Covid-19

Currently open trials in the same condition.

NCT05943743 — Hiccups and Obstacles Of E-Learning Among Medical Sudents · recruiting
NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting
NCT04360538 — Long Term Outcomes of Patients With COVID-19 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04654416 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clínica Medellín - Grupo Quirónsalud
Last refreshed: 4 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04654416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing